Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tart Cherry and Omega-3's for AIMSS in Breast Cancer
NCT06123286Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) (2 arms). Primary endpoint: Changes in joint function at 6 months. Started Sep 2025; status: recruiting.
02
Conditions
Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS)
Beyond the preview
Go deeper on NCT06123286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123286.